3F8 anti-GD2 monoclonal antibody
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for 3F8 anti-GD2 monoclonal antibody, covering 2013-06-28 to 2013-06-28. Get the full timeline:
Most recent: Clinical Trial Update: Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma [Phase 2]